Resurgence of persisting non-cultivable Borrelia burgdorferi following antibiotic treatment in mice

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  Hodzic, Emir ^a   Imai, Denise ^a   Feng, Sunlian ^a   Barthold, Stephen W ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL DNA; CEFTRIAXONE; CYTOKINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL GENE; BACTERIAL GROWTH; BACTERIAL SURVIVAL; BACTERIUM IDENTIFICATION; BORRELIA BURGDORFERI; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOWN REGULATION; DRUG EFFICACY; FEMALE; FLAB GENE; GENE DOSAGE; GENE FUNCTION; GENE IDENTIFICATION; HISTOPATHOLOGY; HOST PATHOGEN INTERACTION; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; LYME DISEASE; MOUSE; NONHUMAN; PARASITE EXAMINATION; POLYMERASE CHAIN REACTION; RNA TRANSCRIPTION; TIC; UPREGULATION; XENODIAGNOSIS;

ANIMALS; ANTI-BACTERIAL AGENTS; BORRELIA BURGDORFERI; CEFTRIAXONE; DNA, BACTERIAL; DOGS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; IMMUNOENZYME TECHNIQUES; LYME DISEASE; MICE; MICE, INBRED C3H; POLYMERASE CHAIN REACTION; RECURRENCE; SPIROCHAETALES; XENODIAGNOSIS;

EID: 84899865015     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0086907     Document Type: Article

References (50)

1. Barthold SW, deSouza MS, Janotka JL, Smith AL, Persing DH (1993) Chronic Lyme borreliosis in the laboratory mouse. Am J Pathol 143: 951-971.
2. Baum E, Hue F, Barbour AG (2012) Experimental infections of the reservoir species Peromyscus leucopus with diverse strains of Borrelia burgdorferi, a Lyme disease agent. MBio 3: e00434-12.
3. Donahue JG, Piesman J, Spielman A (1987) Reservoir competence of white-footed mice for Lyme disease spirochetes. Am J Trop Med Hyg 36: 92-96. (Pubitemid 17033983)
4. Schwan TG, Burgdorfer W, Schrumpf ME, Karstens RH (1988) The urinary bladder: a consistent source of Borrelia burgdorferi in experimentally infected whitefooted mice (Peromyscus leucopus). J Clin Microbiol 26: 893-895.
5. Moody KD, Barthold SW, Terwilliger GA, Beck DS, Hansen GM, et al. (1990) Experimental chronic Lyme borreliosis in Lewis rats. Am J trop Med Hyg 42: 65-74.
6. Goodman JL, Jurkovich P, Kodner C, Johnson RC (1991) Persistent cardiac and urinary tract infections with Borrelia burgdorferi in experimentally infected Syrian hamsters. J Clin Microbiol 29: 894-896.
7. Sonnesyn SW, Manivel JC, Johnson RC, Goodman JL (1993) A guinea pig model for Lyme disease. Infect Immun 61: 4777-4784. (Pubitemid 23320535)
8. Preac-Mursic V, Patsouris E, Wilske B, Reinhardt S, Gos B, et al. (1990) Persistence of Borrelia burgdorferi and histopathological alterations in experimentally infected animals; comparison with histopathological findings in human Lyme disease. Infection 18: 332-341.
9. Straubinger RK, Summers BA, Chang YF, Appel MJG (1997) Persistence of Borrelia burgdorferi in experimentally infected dogs after antibiotic treatment. J Clin Microbiol 35: 111-116. (Pubitemid 26422637)
10. Roberts ED, BohmJr RP, Cogswell FB, Lanners HN, Lowrie Jr RC, et al. (1995) Chronic Lyme disease in the rhesus monkey. Lab Invest 72: 146-160.
11. Hefty PS, Brooks CS, Jett AM, White GL, Wikel SK, et al. (2002) OspE-related, OspF-related, and Elp lipoproteins are immunogenic in baboons experimentally infected with Borrelia burgdorferi and in human Lyme disease patients. J Clin Microbiol 40: 4256-4265. (Pubitemid 35285822)
12. Li X, McHugh GA, Damle N, Sikland VI, Glickstein L, et al. (2011) Burden and viability of Borrelia burgdorferi in skin and joints of patients with erythema migrans or Lyme arthritis. Arthritis Rheum 63: 2238-2247.
13. Embers M, Barthold SW (2012) Borrelia burgdorferi Persistence Post-Antibiotic Treatment. In: Embers ME, editor. The Pathogenic Spirochetes: Strategies for Evasion of Host Immunity and Persistence New York: Springer. 229-252.
14. Barthold SW, Hodzic E, Imai D, Feng S, Yang X, et al. (2010) Ineffectiveness of tigecycline against persistent Borrelia burgdorferi. Antimicrob Agents Chemother 54: 643-651.
15. Bockenstedt LK, Mao J, Hodzic E, Barthold SW, Fish D (2002) Detection of attenuated, non-infectious spirochetes after antibiotic treatment of Borrelia burgdorferi-infected mice. J Infect Dis 186: 1430-1437. (Pubitemid 35286110)
16. Bockenstedt LK, Gonzalez DG, Hamberman AM, Belperron A (2012) Spirochete antigens persist near cartilage after murine Lyme borreliosis therapy. J Clin Invest 122: 2652-2660.
17. Hodzic E, Feng S, Holden K, Freet KJ, Barthold SW (2008) Persistence of Borrelia burgdorferi following antibiotic treatment in mice. Antimicrob Agents Chemother 52: 1728-1736. (Pubitemid 351614666)
18. Yrianainen H, Hytonen J, Soderstrom KO, Oksi J, Hartiala K, et al. (2006) Persistent joint swelling and Borrelia-specific antibodies in Borrelia garinii-infected mice after eradication of vegetative spirochetes with antibiotic treatment. Microbes Infect 8: 2044-2051. (Pubitemid 44311576)
19. Yrjanainen H, Hyotenen J, Song SR, Oksi J, Hartiala K, et al. (2007) Antitumor necrosis factor-alpha treatment activates Borrelia burgdorferi spirochetes in 4 weeks after ceftriaxone treatment in C3H/He mice. J Infect Dis 195: 1489-1496. (Pubitemid 46717467)
20. Yrjanainen H, Hytonen J, Hartiala P, Oksi J, Viljanen MK (2010) Persistence of borrelial DNA in the joints of Borrelia burgdorferi-infected mice after ceftriaxone treatment. APMIS 118: 665-673.
21. Straubinger RK, Straubinger AF, Summers BA, Jacobson RH (2000) Status of Borrelia burgdorferi infection after antibiotic treatment and the effects of corticosteroids: An experimental study. J Infect Dis 181: 1069-1081. (Pubitemid 30194494)
22. Embers M, Barthold SW, Borda JT, Bowers L, Doyle L, et al. (2012) Persistence of Borrelia burgdorferi in rhesus macaques following antibiotic treatment of disseminated infection. PLoS ONE 7: e29914.
23. Battafarano DF, Combs JA, Enzenauer RJ, Fitzpatrick JE (1993) Chronic septic arthritis caused by Borrelia burgdorferi. Clinical Orthop 297: 238-241. (Pubitemid 24000659)
24. Bradley JF, Johnson RC, Goodman JL (1994) The persistence of spirochetal nucleic acids in active Lyme arthritis. Ann Int Med 120: 487-489. (Pubitemid 24075227)
25. Oksi J, Marjamaki M, Nikoskelainen J, Viljanen MK (1999) Borrelia burgdorferi detected by culture and PCR in clinical relapse of disseminated Lyme borreliosis. Ann Med 31: 225-232. (Pubitemid 29304461)
26. Picha D, Moravcova L, Holeckova D, Zd'arsky E, Valesova M, et al. (2008) Examination of specific DNA by PCR in patients with different forms of Lyme borreliosis. Int J Dermatol 47: 1004-1010.
27. Priem S, Burmester GR, Kamradt T, Wolbart K, Rittig MG, et al. (1998) Detection of Borrelia burgdorferi by polymerase chain reaction in synovial membrane, but not in synovial fluid from patients with persisting Lyme arthritis after antibiotic therapy. Ann Rheum Dis 57: 118-121. (Pubitemid 28177543)
28. Wormser GP, Schwartz I (2009) Antibiotic treatment of animals infected with Borrelia burgdorferi. Clin Microbiol Rev 22: 387-395.
29. Wormser GP, Dattwyler RJ, Shapiro ED, Halperin JJ, Steere AC, et al. (2006) The clinical assessment, treatment, and prevention of Lyme disease, human granulocytic anaplasmosis, and babesiosis: clinical practice guidelines by the Infectious Diseases Society of America. Erratum in: Clin Infect Dis 45: 941, 2007. Clin Infect Dis 43: 1089-1134.
30. Barthold SW, Cadavid D, Philipp MT (2010) Animal Models of Borreliosis. In: Samuels DS, Radolph JD, editors. Borrelia: Molecular Biology, Host Interaction and Pathogenesis. Norfolk, UK: Caister Academic Press. 359-411.
31. AVMA (2013) AVMA Guidelines for the Euthanasia of Animals: 2013 Edition. Schumberg, IL: American Veterinary Medical Association.
32. Barbour AG (1984) Isolation and cultivation of Lyme disease spirochetes. Yale J Biol Med 57: 521-525.
33. Moody KD, Adams RL, Barthold SW (1994) Effectiveness of antimicrobial treatment against Borrelia burgdorferi infection in mice. Antimicrob Agents Chemother 38: 1567-1572. (Pubitemid 24203570)
34. Hodzic E, Feng S, Freet K, Barthold SW (2003) Borrelia burgdorferi population dynamics and prototype gene expression during infection of immunocompetent and immunodeficient mice. Infect Immun 71: 5042-5055. (Pubitemid 37070747)
35. Hodzic E, Feng S, Barthold SW (2013) Assessment of transcriptional activity of Borrelia burgdorferi and host cytokine genes during early and late infection in a mouse model. J Vector Borne Dis 13: 694-711.
36. Armstrong AL, Barthold SW, Persing DH, Beck DS (1992) Carditis in Lyme disease susceptible and resistant strains of laboratory mice infected with Borrelia burgdorferi. Am J Trop Med Hyg 47: 249-258.
37. Hodzic E, Feng S, Freet KJ, Borjesson DL, Barthold SW (2002) Borrelia burgdorferi population kinetics and selected gene expression at the host-vector interface. Infect Immun 70: 3382-3388. (Pubitemid 34665973)
38. Schutzer SE, Fraser-Liggett CM, Casjens SR, Qui WG, Dunn JJ, et al. (2011) Whole-genome sequences of thirteen isolates of Borreia burgdorferi. J Bacteriol 193: 1018-1020.
39. Pfaffl MW, Horgan GW, Dempfle L (2002) Relative expression software tool (REST) for group-wise comparison and statistical analysis of relative expression results in real-time PCR. Nucleic Acids Res 30: e36.
40. Barthold SW, Hodzic E, Tunev S, Feng S (2006) Antibody-mediated disease remission in the mouse model of Lyme borreliosis. Infect Immun 74: 4817-4825. (Pubitemid 44157269)
41. Feng S, Hodzic E, Stevenson B, Barthold SW (1998) Humoral immunity to Borrelia burgdorferi N40 decorin binding proteins during infection of laboratory mice. Infect Immun 66: 2827-2835. (Pubitemid 28261792)
42. Wang E, Bergeron Y, Bergeron MG (2005) Ceftriaxone pharmacokinetics in interleukin-10-treated murine pneumococcal pneumonia. J Antimicrob Chemother 55: 721-726. (Pubitemid 40691852)
43. Koomanachai P, Crandon JL, Banevicius MA, Peng L, Nicolau DP (2009) Pharmakodynamic profile of tigecycline against methicillin-resistant Staphylococcu aureus in an experimental pneumonia model. Antimicrob Agents Chemother 53: 5060-5063.
44. Wormser GP, Nadelman RB, Dattwyler RJ, Dennis DT, Shapiro ED, et al. (2000) Practice guidelines for the treatment of Lyme disease. Clin Infect Dis 31 (Supplement 1): S1-S14. (Pubitemid 32293590)
45. MacDonald AB, Berger BW, Schwan TG (1990) Clinical implications of delayed growth of the Lyme borreliosis spirochete, Borrelia burgdorferi. Acta Trop 48: 89-94. (Pubitemid 20385661)
46. Barthold SW, deSouza M, Feng S (1996) Serum-mediated resolution of Lyme arthritis in mice. Lab Invest 74: 57-67. (Pubitemid 26041009)
47. Barthold SW, Feng S, Bockenstedt LK, Fikrig E, Feen K (1997) Protective and arthritis-resolving activity in serum from mice infected with Borrelia burgdorferi. Clin Infect Dis 25: S9-S17.
48. Imai D, Hodzic E, Barthold SW (2013) Dynamics of connective tissue localization during chronic Borrelia burgdorferi infection. Lab Invest 93: 900-910.
49. Tunev SS, Hastey CJ, Hodzic E, Feng S, Barthold SW, et al. (2011) Lymphadenopathy during Lyme borreliosis is caused by spirochete migration-induced specific B cell activation. PLoS Pathog 7: e1002066.
50. Straubinger RK, Straubinger AF, Summers BA, Jacobson RH, Erb HN (1998) Clinical manifestations, pathogenesis, and effect of antibiotic treatment on Lyme borreliosis in dogs. Wien Klin Wochednschr 110: 874-881. (Pubitemid 29067791)